asbestos mesothelioma symptoms
Users of asbestos and mesothelioma patients?
Is it inevitable that every person who worked with asbestos mesothelioma receive? What are the symptoms?
Mesothelial cells normally line the body cavities including the pleura, peritoneum, pericardium, and testis. Malignancies involving mesothelial cells in these body cavities are known as malignant mesothelioma, which may be localized or diffuse. Diagnosis is difficult because the results of the analysis of fluid from the outpouring of the tumor is usually not diagnostic. Most, but not all, malignant pleural mesothelioma is associated with exposure to asbestos. Of the patients with malignant pleural mesothelioma, 77% have been exposed to asbestos in the past. * The median survival for patients with malignant Mesothelioma is 11 months. It is almost always fatal. Median survival based on histologic type is 9.4 months for sarcomatous, 12.5 months for epithelial, and 11 months for mixed. Approximately 15% of patients have an indolent course. * Exposure to asbestos is linked to at least 50% of patients developing mesothelioma malignant. Approximately 8 million people in the United States have been exposed to asbestos in the workplace. Family members are also exposed to asbestos embedded in the worker's clothes. The combination of snuff and asbestos exposure greatly increases the risk of the development history of pleural mesothelioma: * Shortness of breath and pains in nonpleuritic chest wall are the most common presenting symptom. chest radiographs * show obliteration of the diaphragm, nodular thickening of the pleura, decreased breast size in question and / or radiolucent sheetlike lining of the pleura. * A loculated effusion is present in more than 50% of patients, and an important part of the pleura is often overshadowed by the spill. * Chest discomfort, pleuritic pain, easy fatigability, fever, sweats, and weight loss are the other common accompanying symptoms. Patients may also be asymptomatic, with evidence of pleural effusion noted incidentally on physical examination or by radiography Chest. Metastatic disease is rare in the presentation and contralateral pleural abnormalities are usually secondary to asbestos-related diseases pleural rather than metastatic disease. * Approximately 60-90% of patients may have symptoms of chest pain or dyspnea. Physics: * The physical findings of effusion pleural usually detected on percussion and auscultation. * In rare cases, malignant mesothelioma manifests as compression of the spinal cord, brachial plexopathy, Horner syndrome, or vena cava syndrome. Death is usually due to infection or respiratory failure of progression of mesothelioma. * Primary sites include the pleura (87%), peritoneum (5.1%), pericardium (0.4%), and the right side of the thorax (rather than the left side in a ratio of 1.6:1) Causes: * A substantial proportion of patients were exposed to asbestos in asbestos factories, shipping yards, mines, or from their homes. * Crocidolite in asbestos associated with mesothelioma in the miners, manufacturers (with asbestos) and the heating and construction workers. The rod-shaped amphibole are more carcinogenic than chrysotile. * Malignant mesothelioma has also been linked to radiation therapy using thorium dioxide and zeolite, a silicate in the soil. * A causal role of simian virus 40 in malignant mesothelioma has also been suggested. Asbestos exposure alone was associated with malignant mesothelioma SV 40, but was not alone. Giving some epidemiological evidence that SV 40 is a cocarcinogen possible. Its direct role at this point is still controversial. * Interleukin 8 has a direct growth enhancing activity in mesothelial cell lines. Medical Care: Treatment options for the management of malignant mesothelioma include surgery, chemotherapy, radiation and multimodal treatment. * Chemotherapy or present, single-agent cisplatin was used as a drug for phase III clinical trials. None of the standard treatment options has improved survival. The most active agents are anthracyclines, platinum and alkylating agents, each one produces a response rate of 10-20%. O Vogelzang et al presented results of a phase III study of pemetrexed in combination with cisplatin versus cisplatin alone. Pemetrexed (500 mg/m2/d) and cisplatin (75 mg/m2/d) and cisplatin (75 mg/m2/d) was given on day 1. Both arms given every 21 days. The median survival time in group cisplatin / pemetrexed arm was 12.1 months versus 9.3 months for cisplatin alone. The response rate was 41.3% for the cisplatin / pemetrexed arm and 16.7% to the cisplatin. Folic acid and vitamin B-12 was routinely administered to prevent adverse effects of pemetrexed. This study establishes the system as the standard choice for this disease. o A 1999 phase II study by Byrne et al use of cisplatin (100 mg/m2) on day 1 and gemcitabine (1000 mg/m2) given through intravenously on days 1, 8 and 15 of a 28-day cycle for 6 cycles showed response rates of 47.6% (complete and partial response), 42.8% (stable disease), and 9.5% (progressive disease). The length of the average response was 25 weeks, progression-free survival was 25 weeks, and overall survival was 41 weeks. Toxicity was mainly gastrointestinal and hematologic in nature. Or several other combinations have been found to be active, such as cisplatin / doxorubicin (Adriamycin) / mitomycin C, bleomycin / intrapleural hyaluronidase, cisplatin, gemcitabine / doxorubicin (Adriamycin), carboplatin / and cisplatin / vinblastine / mitomycin C. Cisplatin / gemcitabine combination has worked best. O With the isolation of mesothelial cell lines, several chemotherapeutic agents are actively trying to assess its effectiveness. One explanation for the poor response to chemotherapy is the low rate of apoptosis, as demonstrated by low BCL2 and Bax expression. These data suggest that apoptosis is a key phenomenon in the development of mesothelioma and histologic differentiation. Numerous trials of chemotherapeutic agents or their made, however, until recently, the studies were small, the staging systems used were different, and measures of disease were inaccurate. * Results of radiation or radiation therapy are also disappointing. or radiation has no effect on survival, but has caused palliation significant at 50% of patients treated for chest pain and chest wall metastases. * Trimodality or This therapy involves a combination of the 3 standard strategies (ie surgery, chemotherapy, radiation). o One of the approaches involved trimodality extrapleural pneumonectomy followed by combination chemotherapy and radiotherapy. Overall survival rates were 45% at 2 years and 22% at 5 years. Or lymph node involvement was an important negative prognostic factor. The epithelial had a better survival rate compared with sarcomatous or mixed type (65% vs 20% at 2 and 27% and 0% in 5 years). Or survivor at the Brigham system classification was 22 months for stage I, 17 months for stage II and 11 months for stage III. or median overall survival was 17 months, obtaining 2-survival rate 36% and a 5-year survival of 14%. Epithelial cell type survival was better with a 2-year survival of 68% and 5-year survival of 46%. Or different chemotherapeutic regimens found to be useful in treating trimodality include cyclophosphamide / doxorubicin (Adriamycin) / cisplatin, carboplatin / Paclitaxel and cisplatin / methotrexate / vinblastine. External beam radiotherapy delivered in a standard fractionation over 5.5-6 weeks. Surgical Treatment: Resection surgery has been invoked by radiation and chemotherapy have been ineffective primary treatment. The 2 surgical procedures used are pleurectomy with decortication and extrapleural pneumonectomy. * Pleurectomy with decortication is a more limited and requires less cardiorespiratory reserve. This is the dissection of the parietal pleura, incision of the parietal pleura, and decortication of the visceral pleura, followed by reconstruction. Has a mortality rate of 25% and a mortality rate 2%. It is a difficult procedure because the tumor involves the whole pleura, the local recurrence rate is high. * Extrapleural pneumonectomy is a more comprehensive and has a higher mortality rate. Recently, the mortality rate has fallen to 3.8%. They are dissecting the parietal pleura, the division of the vessels lung and en bloc resection of the lung, pleura, pericardium and diaphragm, followed by reconstruction. It provides the best local control, since it eliminates the sack complete with pleural lung parenchyma. * With surgery alone, the recurrence rate is very high and most patients die after a few months. At least half of patients with local control with surgery have distant metastasis at autopsy. Queries: * If an infection suggests a principle, consultation with a pulmonary specialist is essential if the infection is not resolved within 2 weeks with appropriate antibiotic therapy. chest radiographs * are required for monitoring whether the infection has resolved. If the patient has a diffuse calcification of the pleura and a history of weight loss with chronic cough, a comprehensive evaluation by a pulmonary specialist and oncologist is necessary. * A reference to thoracoscopy is warranted if the diagnosis is considered and the initial work is not diagnostic. * Occupational history is important and family members with exposure to asbestos should also be evaluated. Diet: * Patients are often emaciated after surgery, chemotherapy and radiation. Good supportive care and regular evaluation of nutritional status are warranted. Patients should be referred to a nutritionist. Activity: * From physical activity as soon as possible is important to prevent postoperative complications. * Pulmonary physiotherapy is useful because of extensive lung resection in these patients.
Mesothelioma Symptoms and Diagnosis
